Clinical Trials Logo

Filter by:
  • Withdrawn  
  • Page [1]
NCT ID: NCT02237846 Withdrawn - Clinical trials for Osteoarthritis of the Knee

Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis

Start date: September 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Allogeneic human umbilical cord tissue-derived stem cells injected intravenously (IV) once per day for 3 days or once intra-articularly are a safe and will induce a therapeutic effect in osteoarthritis (OA) patients.

NCT ID: NCT02237547 Withdrawn - Spinal Cord Injury Clinical Trials

Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury

Start date: September 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Human Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSC) and Bone Marrow Mononuclear Cells (BMMC) from the patient injected into the spinal fluid intrathecally and injected intravenously (IV) is a safe and therapeutic procedure for spinal cord injury (SCI) patients.

NCT ID: NCT02003131 Withdrawn - Clinical trials for Osteoarthritis of the Knee

Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis

Start date: December 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Allogeneic mesenchymal trophic factors (MTF) from human umbilical cord tissue-derived mesenchymal stem cells (UC-MSC) injected into the knee joints of 20 patients (group 1) or injected subcutaneously into 20 patients (group 2) is a safe and useful procedure for inducing joint function improvements in osteoarthritis (OA) patients with grade 2, 3, or 4 radiographic OA severity.

NCT ID: NCT01885832 Withdrawn - Osteoarthritis Clinical Trials

Safety and Feasibility Study of Autologous Stromal Vascular Fraction (SVF) Cells for Treatment of Osteoarthritis

Start date: June 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Autologous stromal vascular fraction (SVF) injected into joints of 20 patients with grade 2, 3, or 4 radiographic OA severity will be safe and feasible as assessed by lack of treatment associated adverse events. Improvements in joint function as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) are anticipated.

NCT ID: NCT01885819 Withdrawn - Clinical trials for Rheumatoid Arthritis

Autologous Adipose Tissue Stromal Vascular Fraction Cells for Rheumatoid Arthritis

Start date: June 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Autologous stromal vascular fraction (SVF) injected at 8 and 10 days after extraction is safe and useful procedure in inducing remission of RA in patients resistant to standard DMARD therapy.